

Paul S. Anderson

Dr. Anderson obtained his B.S. in chemistry from the University of Vermont in 1959 and his Ph.D. in chemistry with R. E. Lyle at the University of New Hampshire in 1963. After a postdoctoral appointment with Professor Meinwaid at Cornell, he joined the Merck Sharp and Dohme Research Laboratories where he quickly moved from Senior Research Chemist to Research Fellow to Director of the Medicinal Chemistry Department to Vice President for Chemistry at the West Point research facility. He was Senior Vice President of Chemical and Physical Sciences for the DuPont Pharmaceuticals Company in Wilmington, Delaware. Dr. Anderson is currently Vice President, Drug Discovery, Bristol-Myers Squibb Company in Wilmington.

Dr. Anderson and his co-workers at Merck were involved in research directed at the design and synthesis of molecules that act at neurotransmitter receptors such as MK-801, enzyme inhibitors such as simvastatin, a potent cholesterol lowering compound, and drugs for the treatment of glaucoma. These studies led to TRUSOPT, the first topically active carbonic anhydrase inhibitor for treating glaucoma and ZOCOR, the most frequently prescribed drug for lowering cholesterol levels.

More recently, Dr. Anderson has directed extensive medicinal chemistry efforts at Merck and DuPont Pharmaceuticals Company committed to discovery of new chemotherapy for AIDS. These efforts led to synthesis of inhibitors of HIV-1 reverse transcriptase and of HIV protease. The HIV protease inhibitor, CRIVAN, and the HIV reverse transcriptase inhibitor, SUSTIVA, resulted from this work.

Dr. Anderson served as Chairman of the Medicinal Chemistry Division of the American Chemical Society in 1987, Chairman of the 1991 Gordon Research Conference on Medicinal Chemistry and member (1985-1988) and then Chairman of the NIH Study Section on Bioorganic Chemistry and Natural Products, 1988-1989. More recently he has been a member of the Advisory Council of the National Institutes of General Medical Sciences at the National Institutes of Health and the National Research

Council, Board on Chemical Sciences and Technology. In 1997 he served as President of the American Chemical Society. Dr. Anderson is a founding member of the KU School of Pharmacy's Executive Advisory Council.

Dr. Anderson was the 1995 recipient of the American Chemical Society's E.B. Hershberg Award for important discoveries in medicinally-active substances. He received a Doctor of Science Honoris Causa from the University of Vermont in 1998. In 2001, he was the recipient of the American Chemical Society Award in Industrial Chemistry and a Doctor of Chemistry Honoris Causa from the University of New Hampshire. Dr. Anderson is the recipient of the 2002 Perkin Medal.